KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Current Deferred Revenue (2019 - 2020)

Boston Scientific's Current Deferred Revenue history spans 7 years, with the latest figure at $309.0 million for Q3 2025.

  • For Q3 2025, Current Deferred Revenue rose 6.55% year-over-year to $309.0 million; the TTM value through Sep 2025 reached $309.0 million, up 6.55%, while the annual FY2024 figure was $306.0 million, 15.04% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $309.0 million at Boston Scientific, down from $349.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $349.0 million in Q2 2025 and bottomed at $139.0 million in Q1 2021.
  • The 5-year median for Current Deferred Revenue is $289.0 million (2022), against an average of $277.2 million.
  • The largest annual shift saw Current Deferred Revenue skyrocketed 100.72% in 2022 before it fell 7.96% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $208.0 million in 2021, then soared by 38.94% to $289.0 million in 2022, then dropped by 7.96% to $266.0 million in 2023, then rose by 15.04% to $306.0 million in 2024, then grew by 0.98% to $309.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Current Deferred Revenue are $309.0 million (Q3 2025), $349.0 million (Q2 2025), and $335.0 million (Q1 2025).